| NCT ID | NCT06786663 |
| Status | Recruiting |
| Phase | — |
| Sponsor | Regina Elena Cancer Institute |
| Condition | Breast Neoplasms, Male |
| Study Type | OBSERVATIONAL |
| Enrollment | 7 participants |
| Start Date | 2024-04-19 |
| Primary Completion | 2027-04-19 |
Eligibility & Interventions
Eligibility Fast-Check
Enter your details for a quick preliminary check. This does not replace medical advice.
What to Expect as a Participant
This is an observational study. You will not receive an experimental treatment; researchers will collect data based on your existing condition or standard treatment.
This trial targets 7 participants in total. It began in 2024-04-19 with a primary completion date of 2027-04-19.
⚠ This information is for research awareness only. Always consult your physician before joining any clinical trial. Participation is voluntary and you may withdraw at any time.
Brief Summary
It is believed that the use of organoids derived from male breast tumors can be of fundamental support for the definition of the molecular mechanisms underlying the onset of the tumor. Furthermore, the development of such preclinical models could be of significant support for the identification of specific personalized and ad hoc therapeutic treatments for male pathology.
Eligibility Criteria
Inclusion Criteria: * Men aged \>18 years * Patients with histologically confirmed breast cancer with or without synchronous metastases, who will undergo the relevant surgical intervention * Adequate biological material to be able to carry out the analyses described above * Signing of the relevant informed consent form Exclusion Criteria: not present
Contact & Investigator
Frequently Asked Questions
Who can join the NCT06786663 clinical trial?
This trial is open to male participants only, aged 18 Years or older, studying Breast Neoplasms, Male. Full inclusion and exclusion criteria are listed in the Eligibility Criteria section. Always confirm your eligibility with the research team before applying.
Is NCT06786663 currently recruiting?
Yes, NCT06786663 is actively recruiting participants. Contact the research team at giovanni.blandino@ifo.it for enrollment information.
Where is the NCT06786663 trial being conducted?
This trial is being conducted at Rome, Italy.
Who is sponsoring the NCT06786663 clinical trial?
NCT06786663 is sponsored by Regina Elena Cancer Institute. The trial plans to enroll 7 participants.